I don't think people here are thinking in very big
Post# of 145747
![](/assets/46931549/no_avatar_available_thumb.jpg)
CDiddy is right - BP is not willing to pay us for what we think Cytodyn is worth and Pourhassen is not willing to sell for anything less.
As I see it, we are still on our way from being a itty-bitty company to becoming a behemoth.
Try thinking of all the events and timelines of the future as just "The Future." It looks like a big funnel and we are at the small end of the big funnel, expanding going forward - Hey, just like the Big Bang!
We have before us the huge task of expanding manufacturing, testing Leronlimab against a huge list of indications, building the teams to do that, getting FDA approvals, marketing, etc.
Above all, this means more people and more people means compensation.
I wrote somewhere months back that I thought Cytodyn, with so many indications to work on, should set up a bunch of wholly owned companies to each take on a few indications and let them run with them. I envision it like partnerships.
This is just a wild stab at a structure that would delegate tasks and responsibilities to talented teams. It makes sense to me but that is one way to get to the big end of the funnel without getting spread too thin and being distracted.
I liked this model because I thought it made compensation issues pretty clear and easy too. Everything is not in one big wad, demanding direction from the top - too top centric.
This isn't feasible but what if each scientific advisor was given a division to run? How would you compensate them then?
Just dreaming about expansion and the big funnel of the future!
We will have to pay for it with some stock along the way!
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)